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The quest for new therapeutics and better
follow-up of patients with inflammatory
bowel diseases (IBD) requires the clear-
est possible picture of the immunolog-
ical mechanisms underlying these com-
plex pathologies. We identified recently
a potential new player in this destruc-
tive game, a non-conventional T cell sub-
set called Mucosal-Associated Invariant
T (MAIT) cells. These cells were ini-
tially identified on the basis of their use
of a semi-invariant TCR, made of the
invariant Vα7.2–Jα33 TCRα chain (now
TCRAV1S2–AJ33) paired to a limited num-
ber of different TCRβ chains (1). Human
MAIT cells are mostly CD8+ T cells
with an effector/memory phenotype and
expression of various chemokine recep-
tors involved in extra-lymphoid migration.
They also express most markers associ-
ated with IL-17 producing T cells, such as
RORγt, high CD161, IL-23R, and CD26.
They make up to 10% of peripheral blood
and intestinal lamina propria T cells, and
are even more abundant in the liver (2).
The most striking feature of MAIT cells
is their recognition of highly conserved
microbial-derived metabolites associated
to a monomorphic MHC class-I like mole-
cule, MR1 (MHC-related 1) (3). These lig-
ands structurally belong to the pterin fam-
ily and are derived from the riboflavin syn-
thesis pathway. Recent experiments showed
that virtually all MAIT cells are stained
by fluorescent MR1 tetramers loaded with
these specific metabolites. This pathway
is absent in vertebrates, but many bacte-
rial and fungal species produce riboflavin
and therefore, MAIT cells-specific ligands.
In this respect, these metabolites behave
like microbial innate signals, and may alert
MAIT cells that an invasive infection is on-
going. Upon activation, MAIT cells release
TNFα, IFNγ and become cytotoxic; they
also produce IL-17 in specific conditions.
In fact, they represent the great major-
ity of naturally occurring IL-17-producing
CD8+ T cells in the human peripheral
blood. These cells are very likely to perform
important anti-microbial functions,as sug-
gested in humans and mice models (4).
However, numerous reports suggest that
MAIT cells are recruited from the blood
to inflamed tissues in chronic inflamma-
tory diseases such as multiple sclerosis, pso-
riasis, and systemic lupus, among others.
We recently showed that Crohn’s disease
(CD) patients display a decreased number
of blood MAIT, balanced by their accu-
mulation in the inflamed portions of the
gut (5). As already stated, MAIT cells are
equipped with chemokine receptors allow-
ing migration toward tissues, in particular
in conditions of inflammation. Therefore,
it might be suggested that they are non-
specifically attracted to sites of inflamma-
tion and are only bystanders in this process.
However, we wish to discuss in this opinion
article the arguments in favor of a relevant
role for this T cell subset, at least in the
context of CD.
We showed in our study that blood
MAIT cells from CD patients showed an
altered phenotype, increased in vivo pro-
liferation, and, interestingly, a shift in
cytokine production with decreased IFNγ
and increased IL-17 production (5). While
this description does not allow any formal
conclusions about the direct involvement
of MAIT cells in the pathophysiology of
the disease, it has several important impli-
cations. Indeed, although blood MAIT
cells may be non-specifically attracted
to the inflamed gut by locally produced
chemokines, it must be reminded that a sig-
nificant number of them are found in the
gut lamina propria in the healthy intestine.
Therefore, it is more than likely that these
intestinal cells are also activated in CD, and
produce cytokines, which are highly rel-
evant to the pathology, i.e., IFNγ, TNFα,
and IL-17. Hence, it is difficult to suggest
that these local cells (as well as newcomers
from blood), strongly activated and pro-
ducing inflammatory cytokines, have no
consequences on the local inflammation.
The question that needs to be addressed is
the mechanisms by which MAIT cells may
be activated; we propose two non-mutually
exclusive hypotheses:
1. The microbial ligands recognized by
the MAIT cells TCR (named RL anti-
gens after their ribityl-lumazine com-
position) derive from a conserved path-
way of riboflavin synthesis. This path-
way is conserved among many bac-
terial species, and may explain MAIT
cells activation and recruitment in
response to infections by Salmonella
typhimurium, Mycobacterium tubercu-
losis, Shigella flexneri, Vibrio cholerae,
and others. However, these ligands
are also synthetized by non-pathogenic
bacteria, including several species found
in the normal gut microbiota. In mice,
peripheral maturation of MAIT cells
is dependent upon the colonization of
the intestine by the commensal flora.
Therefore, there are strong interactions
between MAIT cells and ligands derived
from the commensal flora. Neverthe-
less, mechanisms must exist to ensure

























































Treiner MAIT cells participation in IBD
that intestinal MAIT cells do not aggres-
sively respond to gut bacteria in the
steady-state. In IBD, the disruption
in local immune homeostasis results
in dysbiosis, increased permeability of
the mucosa, and subsequent increased
bacterial translocation. Therefore, it is
likely that these events induce also
an increased availability of antigens
derived from the commensal flora and
therefore, MAIT cells activation.
2. Human MAIT cells constitutively
express receptors for IL-12, IL-23, and
IL-18. It is now demonstrated that they
can be activated in the absence of their
cognate antigens by a combination of
IL-12+ IL-18 (6). MAIT cells activation
by cytokines result in exclusive IFNγ
secretion, at least in the blood and liver
(7). Furthermore, both cytokines play
an important function in MAIT cells
activation by bacteria, independently
of their capacity to produce riboflavin,
since blocking antibodies to IL-12 and
IL-18 strongly inhibit activation. This
pathway depends on activation of the
inflammasome in monocytes, resulting
in cytokine secretion and MAIT cells
activation in co-culture experiments.
IL-12 and IL-18 are both over-produced
in the intestinal mucosa of CD patients.
IL-23R, NLRP3, IL-18R1, and IL12B2
gene polymorphisms are significantly
associated with CD, further suggesting
a prominent role for these cytokines
in the pathophysiology of the disease.
Therefore, it is likely that this cytokine
environment participates locally in
MAIT cells activation, and may influ-
ence their survival and/or proliferation.
Altogether, the cytokines produced in
large quantities by intestinal antigen-
presenting cells create an environment
that favors MAIT cells activation, both
in the presence and absence of their
cognate antigens.
DR. JEKYLL OR MISTER HYDE?
The next important question is obviously
the role that activated MAIT cells may
play during CD. In most reports describ-
ing MAIT cells implications in autoim-
mune diseases, the authors suggest that
these cells are pro-inflammatory and dele-
terious. This is inferred from the fact that
in vitro mitogen-activated MAIT cells pro-
duce IFNγ, TNFα, and IL-17. Given the
reported inflammatory role for IL-17 in
several chronic inflammatory diseases, this
cytokine secretion pattern is interpreted
strictly as pro-inflammatory. However, it is
important to pinpoint several facts. First, in
most reports, MAIT cells activation in vitro
by riboflavin-producing bacteria induce
mostly IFNγ and TNFα secretion, with
little or no IL-17. Accordingly, cytokines-
induced MAIT cells activation results solely
in IFNγ production. Second, very little is
known about the regulation of cytokine
secretion by MAIT cells in vivo. Of note,
there is no published description of the
functional response of mucosal MAIT cells
to bacteria, their cognate antigens and/or
cytokines. It is likely that the mucosal
specific environment (cytokines, antigen-
presenting cells, and other features) skews
MAIT cells functions, as already described
for conventional T cells. This question is
of great importance in the context of CD,
where the major inflammatory cytokine is
suggested to be IFNγ, although IL-23 and
IL-17 are produced in great quantities in
the inflamed mucosa (8). Indeed, several
studies reported a protective role for IL-
17 in the intestinal mucosa (9, 10), and
clinical trials with the anti-IL-17 antibody
secukinumab demonstrated an absence of
efficiency in CD (11), suggesting IL-17 is
not the major cytokine in the inflamma-
tory process (12). In our own study, we
reported that blood MAIT cells from CD
patients show a shift in cytokine secre-
tion with lower IFNγ and higher IL-17.
Therefore, it is possible that in CD, MAIT
cells recruited from the circulation to the
mucosa display enhanced protective IL-17
secretion in response to the local inflamma-
tion, as an endeavor to heal the aggressed
mucosa. In other words, there is insuffi-
cient data available to demonstrate at this
point that MAIT cells are necessarily pro-
inflammatory, especially in the context of
IBD.
CONCLUDING REMARKS
There is no demonstration to date that
MAIT cells are directly involved in autoim-
mune/inflammatory diseases. However,
there is sufficient data to foster more stud-
ies on this topic, especially in CD. The
main problem is that there is no rele-
vant animal model available, as mice dis-
play a defect in MAIT cells development.
Therefore, it is important to pursue the
analysis of human MAIT cells in vitro
and ex vivo, in healthy donors and CD
patients. There is a need to study these
cells in the mucosa, where they proba-
bly behave differently than at the systemic
level. It will be also useful to analyze the
role that some important gene polymor-
phisms involved in CD may have on MAIT
cells activation and functional response.
Finally, longitudinal analysis of MAIT cells
phenotype and functions in CD patients
undergoing various targeted therapies will
also shed light on their role in the dis-
ease, and, possibly, their potential use as
biomarkers.
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